Jeff is a physician and scientist and serves as the Chief Scientific Officer of ENSEM Therapeutics. He comes to ENSEM with more than 25 years clinical practice, translational scientific research, and biotech leadership experience in oncology, immuno-oncology, and epigenetics. As an experienced biotech executive in the drug development space, Jeff recently served as the Chief Scientific Officer at Epizyme, Inc., where he led the company’s scientific strategy, including directing preclinical research to support the further development of the EZH2 inhibitor, TAZVERIK® (tazemetostat), and advancing the company’s broader epigenetic pipeline. He also served as a member of the leadership team during its acquisition by Ipsen.  Prior to joining Epizyme, he served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company’s scientific strategy, preclinical development, and translational science. During his tenure at Infinity, the company advanced several oral PI3K inhibitors into the clinic. He was also part of the leadership team during the AbbVie partnership and was involved in the licensing of the PI3Kδ/ɣ inhibitor, COPIKTRA® (duvelisib) to Verastem Oncology.

Prior to his industry experience, Jeff was an Associate Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital (BWH) and is board certified in Anatomic Pathology and Hematology. His laboratory at BWH focused on translational medicine research and biomarker identification in oncology and he is a leading expert in cancer biology, with authorship on over 200 journal articles, reviews, and book chapters. Jeff received his B.S. in Biology and his M.D., Ph.D. in Medicine and Molecular Pathology from Stony Brook University.